Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/breast-cancer-heterogeneity-need-to-review-current-treatment-aL4HJgPYfR
References (78)
-
M. Shipitsin, Lauren Campbell, P. Argani, S. Weremowicz, Noga Bloushtain-Qimron, Jun Yao, T. Nikolskaya, T. Serebryiskaya, R. Beroukhim, Min Hu, M. Halushka, S. Sukumar, L. Parker, K. Anderson, L. Harris, J. Garber, A. Richardson, S. Schnitt, Y. Nikolsky, R. Gelman, K. Polyak (2007)
Molecular definition of breast tumor heterogeneity.Cancer cell, 11 3
-
T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. Eisen, M. Rijn, S. Jeffrey, T. Thorsen, H. Quist, J. Matese, P. Brown, D. Botstein, P. Lønning, A. Børresen-Dale (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 98
-
D. Hambardzumyan, M. Squatrito, E. Holland (2007)
Radiation Resistance and Stem-Like Cells in Brain Tumors (DOI: 10.1016/j.ccr.2006.11.008)Cancer Cell, 11
-
P. Stephens, P. Tarpey, H. Davies, P. Loo, C. Greenman, D. Wedge, S. Nik-Zainal, Sancha Martin, I. Varela, G. Bignell, L. Yates, E. Papaemmanuil, D. Beare, A. Butler, Angela Cheverton, John Gamble, Jonathan Hinton, Mingming Jia, Alagurevathi Jayakumar, David Jones, Calli Latimer, K. Lau, Stuart Mclaren, D. Mcbride, A. Menzies, L. Mudie, K. Raine, R. Rad, M. Chapman, J. Teague, D. Easton, A. Langerød, Rolf Ottestad, R. Kåresen, E. Schlichting, B. Naume, Torill Sauer, L. Ottestad, M. Lee, Chen-Yang Shen, Benita Tee, Bernice Huimin, A. Broeks, A. Vargas, G. Turashvili, J. Martens, Aquila Fatima, P. Miron, S. Chin, G. Thomas, S. Boyault, O. Mariani, S. Lakhani, M. Vijver, L. Veer, J. Foekens, C. Desmedt, C. Sotiriou, A. Tutt, C. Caldas, J. Reis-Filho, S. Aparicio, A. Salomon, A. Børresen-Dale, A. Richardson, P. Campbell, P. Futreal, M. Stratton (2012)
The landscape of cancer genes and mutational processes in breast cancerNature, 486
-
H. Korkaya, Amanda Paulson, E. Charafe-Jauffret, C. Ginestier, Marty Brown, J. Dutcher, Shawn Clouthier, M. Wicha (2009)
Regulation of Mammary Stem/Progenitor Cells by PTEN/Akt/β-Catenin SignalingPLoS Biology, 7
-
A. Magnifico, Luisa Albano, S. Campaner, D. Delia, F. Castiglioni, P. Gasparini, G. Sozzi, E. Fontanella, S. Ménard, E. Tagliabue (2009)
Tumor-Initiating Cells of HER2-Positive Carcinoma Cell Lines Express the Highest Oncoprotein Levels and Are Sensitive to TrastuzumabClinical Cancer Research, 15
-
D. Hambardzumyan, M. Squatrito, E. Holland (2006)
Radiation resistance and stem-like cells in brain tumors.Cancer cell, 10 6
-
Min Hu, Jun Yao, Li Cai, K. Bachman, F. Brûle, V. Velculescu, K. Polyak (2005)
Distinct epigenetic changes in the stromal cells of breast cancersNature Genetics, 37
-
M. Al-Hajj, M. Wicha, Adalberto Benito-Hernández, S. Morrison, M. Clarke (2003)
Prospective identification of tumorigenic breast cancer cellsProceedings of the National Academy of Sciences of the United States of America, 100
-
D. Hayes, T. Walker, B. Singh, E. Vitetta, J. Uhr, S. Gross, C. Rao, G. Doyle, L. Terstappen (2002)
Monitoring expression of HER-2 on circulating epithelial cells in patients with advanced breast cancer.International journal of oncology, 21 5
-
T. Fehm, S. Becker, S. Duerr-Stoerzer, K. Sotlar, V. Mueller, D. Wallwiener, N. Lane, E. Solomayer, J. Uhr (2007)
Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 statusBreast cancer research : BCR, 9
-
G. Lindeman, J. Visvader (2010)
Insights into the cell of origin in breast cancer and breast cancer stem cellsAsia‐Pacific Journal of Clinical Oncology, 6
-
B. Hennessy, A. González-Angulo, K. Stemke‐Hale, M. Gilcrease, S. Krishnamurthy, Ju-Seog Lee, J. Fridlyand, A. Sahin, R. Agarwal, C. Joy, Wenbin Liu, D. Stivers, K. Baggerly, M. Carey, A. Lluch, C. Monteagudo, Xiaping He, V. Weigman, C. Fan, J. Palazzo, G. Hortobagyi, L. Nolden, Nicholas Wang, V. Valero, J. Gray, C. Perou, G. Mills (2009)
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.Cancer research, 69 10
-
R. Morris (2004)
A perspective on keratinocyte stem cells as targets for skin carcinogenesis.Differentiation; research in biological diversity, 72 8
-
S. Park, H. Kwon, Yoomi Choi, H. Lee, Sung-Won Kim, J. Kim, In Kim, N. Jung, N. Cho, G. Kang (2012)
Distinct patterns of promoter CpG island methylation of breast cancer subtypes are associated with stem cell phenotypesModern Pathology, 25
-
S. Baylin, Peter Jones (2011)
A decade of exploring the cancer epigenome — biological and translational implicationsNature Reviews Cancer, 11
-
Xiao-Jun Ma, S. Dahiya, E. Richardson, M. Erlander, D. Sgroi (2009)
Gene expression profiling of the tumor microenvironment during breast cancer progressionBreast Cancer Research : BCR, 11
-
M. Allinen, R. Beroukhim, Li Cai, C. Brennan, J. Lahti-Domenici, Haiyan Huang, D. Porter, Min Hu, L. Chin, A. Richardson, S. Schnitt, W. Sellers, K. Polyak (2004)
Molecular characterization of the tumor microenvironment in breast cancer.Cancer cell, 6 1
-
P. Nowell (1976)
The clonal evolution of tumor cell populations.Science, 194 4260
-
B. Lehmann, Joshua Bauer, X. Chen, M. Sanders, A. Chakravarthy, Y. Shyr, J. Pietenpol (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.The Journal of clinical investigation, 121 7
-
M. Diehn, Robert Cho, N. Lobo, T. Kalisky, M. Dorie, A. Kulp, D. Qian, Jessica Lam, Laurie Ailles, Manzhi Wong, Benzion Joshua, Michael Kaplan, I. Wapnir, F. Dirbas, G. Somlo, C. Garberoglio, B. Paz, Jeannie Shen, Sean Lau, Stephen Quake, J. Brown, Irving Weissman, Michael Clarke (2009)
Association of reactive oxygen species levels and radioresistance in cancer stem cellsNature, 458
-
N. Turner, J. Reis-Filho (2012)
Genetic heterogeneity and cancer drug resistance.The Lancet. Oncology, 13 4
-
R. Neve, K. Chin, J. Fridlyand, Jennifer Yeh, F. Baehner, T. Fevr, Laura Clark, N. Bayani, Jean-Philippe Coppé, F. Tong, T. Speed, P. Spellman, S. Devries, A. Lapuk, Nicholas Wang, W. Kuo, J. Stilwell, D. Pinkel, D. Albertson, F. Waldman, F. McCormick, R. Dickson, Michael Johnson, M. Lippman, S. Ethier, A. Gazdar, J. Gray (2006)
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.Cancer cell, 10 6
-
D. Slamon, B. Leyland-Jones, Steven Shak, Hank Fuchs, Virginia Paton, A. Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, M. Pegram, J. Baselga, Larry Norton (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.The New England journal of medicine, 344 11
-
F. Al-Ejeh, C. Smart, B. Morrison, G. Chenevix-Trench, J. Lopez, S. Lakhani, M. Brown, K. Khanna (2011)
Breast cancer stem cells: treatment resistance and therapeutic opportunities.Carcinogenesis, 32 5
-
V. Georgoulias, V. Bozionelou, S. Agelaki, M. Perraki, S. Apostolaki, G. Kallergi, K. Kalbakis, A. Xyrafas, D. Mavroudis (2012)
Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.Annals of oncology : official journal of the European Society for Medical Oncology, 23 7
-
R. Siegel, D. Naishadham, A. Jemal (2012)
Cancer statistics, 2012CA: A Cancer Journal for Clinicians, 62
-
P. Calabrese, S. Tavaré, D. Shibata (2004)
Pretumor progression: clonal evolution of human stem cell populations.The American journal of pathology, 164 4
-
Stephan Braun, G. Schlimok, Isabella Heumos, Gerhard Schaller, Lutz Riethdorf, Gert Riethmüller, K. Pantel (2001)
ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.Cancer research, 61 5
-
C. Perou, T. Sørlie, M. Eisen, M. Rijn, S. Jeffrey, Christian Rees, J. Pollack, D. Ross, H. Johnsen, L. Akslen, Ø. Fluge, Alexander Pergamenschikov, Cheryl Williams, Shirley Zhu, P. Lønning, A. Børresen-Dale, P. Brown, D. Botstein (2000)
Molecular portraits of human breast tumoursNature, 406
-
H. Korkaya, Amanda Paulson, F. Iovino, F. Iovino, M. Wicha (2008)
HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasionOncogene, 27
-
Antonio Wolff, M. Hammond, Jared Schwartz, K. Hagerty, D. Allred, Richard Cote, M. Dowsett, P. Fitzgibbons, Wedad Hanna, A. Langer, L. McShane, S. Paik, M. Pegram, Edith Perez, Michael Press, A. Rhodes, C. Sturgeon, S. Taube, R. Tubbs, Gail Vance, Marc Vijver, Thomas Wheeler, Daniel Hayes (2006)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.Archives of pathology & laboratory medicine, 131 1
-
C. Curtis, Sohrab Shah, S. Chin, G. Turashvili, O. Rueda, M. Dunning, D. Speed, A. Lynch, S. Samarajiwa, Yinyin Yuan, S. Gräf, G. Ha, Gholamreza Haffari, A. Bashashati, R. Russell, S. McKinney, A. Langerød, A. Green, E. Provenzano, G. Wishart, S. Pinder, P. Watson, F. Markowetz, L. Murphy, I. Ellis, A. Purushotham, A. Børresen-Dale, J. Brenton, S. Tavaré, C. Caldas, S. Aparicio (2012)
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 486
-
E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer, N. Davidson, E. Tan-chiu, S. Martino, S. Paik, P. Kaufman, S. Swain, T. Pisansky, L. Fehrenbacher, L. Kutteh, V. Vogel, D. Visscher, G. Yothers, R. Jenkins, A. Brown, S. Dakhil, E. Mamounas, W. Lingle, P. Klein, J. Ingle, N. Wolmark (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.The New England journal of medicine, 353 16
-
Fl Baehner, T. Maddala, C. Alexander, AM Gown, LC Goldstein, NS Achacoso, S. Shak, CP Quesenberry, LA Habel (2009)
Magnetic resonance imaging for diagnosis, staging, and follow-upBreast Cancer Research : BCR, 11
-
K. Anderson, C. Lutz, F. Delft, C. Bateman, Yanping Guo, S. Colman, H. Kempski, A. Moorman, I. Titley, J. Swansbury, L. Kearney, T. Enver, M. Greaves (2011)
Genetic variegation of clonal architecture and propagating cells in leukaemiaNature, 469
-
D. Iliopoulos, H. Hirsch, K. Struhl (2009)
An Epigenetic Switch Involving NF-κB, Lin28, Let-7 MicroRNA, and IL6 Links Inflammation to Cell TransformationCell, 139
-
S. Nass, J. Herman, E. Gabrielson, P. Iversen, F. Parl, N. Davidson, J. Graff (2000)
Aberrant methylation of the estrogen receptor and E-cadherin 5' CpG islands increases with malignant progression in human breast cancer.Cancer research, 60 16
-
D. Hunter, P. Kraft, K. Jacobs, D. Cox, M. Yeager, S. Hankinson, S. Wacholder, Zhaoming Wang, R. Welch, A. Hutchinson, Junwen Wang, Kai Yu, N. Chatterjee, N. Orr, W. Willett, G. Colditz, R. Ziegler, C. Berg, S. Buys, C. McCarty, H. Feigelson, E. Calle, M. Thun, R. Hayes, M. Tucker, D. Gerhard, J. Fraumeni, R. Hoover, G. Thomas, S. Chanock (2007)
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancerNature Genetics, 39
-
N. Houssami, P. Macaskill, R. Balleine, M. Bilous, M. Pegram (2011)
HER2 discordance between primary breast cancer and its paired metastasis: tumor biology or test artefact? Insights through meta-analysisBreast Cancer Research and Treatment, 129
-
N. Bertos, Morag Park (2011)
Breast cancer - one term, many entities?The Journal of clinical investigation, 121 10
-
C. Vogel, M. Cobleigh, Debu Tripathy, John Gutheil, Lyndsay Harris, L. Fehrenbacher, D. Slamon, M. Murphy, William Novotny, M. Burchmore, Steven Shak, S. Stewart, Michael Press (2002)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 3
-
H. Korkaya, Suling Liu, M. Wicha (2011)
Regulation of Cancer Stem Cells by Cytokine Networks: Attacking Cancer's Inflammatory RootsClinical Cancer Research, 17
-
Ç. Arslan, E. Sarı, S. Aksoy, K. Altundağ (2011)
Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literatureExpert Opinion on Therapeutic Targets, 15
-
M. Gerlinger, A. Rowan, S. Horswell, M. Math, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez, N. Matthews, A. Stewart, P. Tarpey, I. Varela, B. Phillimore, Sharmin Begum, N. McDonald, A. Butler, David Jones, K. Raine, Calli Latimer, Claudio Santos, M. Nohadani, A. Eklund, B. Spencer‐Dene, G. Clark, L. Pickering, G. Stamp, M. Gore, Z. Szallasi, J. Downward, P. Futreal, C. Swanton (2012)
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.The New England journal of medicine, 366 10
-
B. Druker, M. Talpaz, D. Resta, B. Peng, E. Buchdunger, J. Ford, N. Lydon, H. Kantarjian, R. Capdeville, Sayuri Ohno-Jones, C. Sawyers (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.The New England journal of medicine, 344 14
-
W. Foulkes, J. Reis-Filho, S. Narod (2010)
Tumor size and survival in breast cancer—a reappraisalNature Reviews Clinical Oncology, 7
-
S. Graham, H. Jørgensen, E. Allan, C. Pearson, M. Alcorn, L. Richmond, T. Holyoake (2002)
Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.Blood, 99 1
-
J. Welch, T. Ley, D. Link, Christopher Miller, D. Larson, D. Koboldt, L. Wartman, T. Lamprecht, Fulu Liu, Jun Xia, C. Kandoth, R. Fulton, M. McLellan, D. Dooling, J. Wallis, Ken Chen, C. Harris, Heather Schmidt, Joelle Kalicki-Veizer, Charles Lu, Qunyuan Zhang, Ling Lin, M. O'Laughlin, Joshua McMichael, K. Delehaunty, L. Fulton, V. Magrini, S. McGrath, Ryan Demeter, T. Vickery, J. Hundal, L. Cook, Gary Swift, Jerry Reed, Patricia Alldredge, T. Wylie, Jason Walker, M. Watson, S. Heath, W. Shannon, Nobish Varghese, R. Nagarajan, J. Payton, J. Baty, S. Kulkarni, J. Klco, M. Tomasson, P. Westervelt, M. Walter, T. Graubert, J. Dipersio, L. Ding, E. Mardis, R. Wilson (2012)
The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 150
-
A. Marusyk, K. Polyak (2010)
Tumor heterogeneity: causes and consequences.Biochimica et biophysica acta, 1805 1
-
A. Vincent-Salomon, J. Pierga, J. Couturier, C. d’Enghien, Claude Nos, B. Sigal‐Zafrani, M. Laé, P. Fréneaux, V. Diéras, J. Thiery, X. Sastre-Garau (2007)
HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?British Journal of Cancer, 96
-
M. Wicha, Suling Liu, G. Dontu (2006)
Cancer stem cells: an old idea--a paradigm shift.Cancer research, 66 4
-
K Polyak (2009)
Breast tumor heterogeneity: causes and consequencesBreast Cancer Res., 11
-
S. Paik, Chungyeul Kim, N. Wolmark (2008)
HER2 status and benefit from adjuvant trastuzumab in breast cancer.The New England journal of medicine, 358 13
-
A. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M. Deininger, B. Druker (2011)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.The Journal of clinical investigation, 121 1
-
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.The New England journal of medicine, 353 16
-
L. Ding, M. Ellis, Shunqiang Li, D. Larson, Ken Chen, J. Wallis, C. Harris, M. McLellan, R. Fulton, L. Fulton, R. Abbott, J. Hoog, D. Dooling, D. Koboldt, Heather Schmidt, Joelle Kalicki, Qunyuan Zhang, Lei Chen, Ling Lin, M. Wendl, Joshua McMichael, V. Magrini, L. Cook, S. McGrath, T. Vickery, Elizabeth Appelbaum, K. Deschryver, S. Davies, Therese Guintoli, Li Lin, R. Crowder, Y. Tao, J. Snider, Scott Smith, Adam Dukes, Gabriel Sanderson, C. Pohl, K. Delehaunty, C. Fronick, Kimberley Pape, Jerry Reed, J. Robinson, J. Hodges, W. Schierding, N. Dees, D. Shen, D. Locke, Madeline Wiechert, James Eldred, Joshua Peck, Benjamin Oberkfell, Justin Lolofie, Feiyu Du, Amy Hawkins, M. O'Laughlin, Kelly Bernard, M. Cunningham, Glendoria Elliott, M. Mason, Dominic Thompson, J. Ivanovich, P. Goodfellow, C. Perou, G. Weinstock, R. Aft, M. Watson, T. Ley, R. Wilson, E. Mardis (2010)
Genome Remodeling in a Basal-like Breast Cancer Metastasis and XenograftNature, 464
-
B. Aktas, M. Tewes, T. Fehm, S. Hauch, R. Kimmig, S. Kasimir-Bauer (2009)
Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patientsBreast Cancer Research : BCR, 11
-
M. Tokunaga, J. Norman, M. Asano, S. Tokuoka, H. Ezaki, I. Nishimori, Y. Tsuji (1979)
Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950-74.Journal of the National Cancer Institute, 62 6
-
Don Conroy, M. Shah, H. Munday, C. Jordan, B. Perkins, Judy West, Karen Redman, K. Driver, Morteza Aghmesheh, D. Amor, Lesley Andrews, Y. Antill, Jane Armes, Shane Armitage, Leanne Arnold, Rosemary Balleine, Glenn Begley, J. Beilby, Ian Bennett, Barbara Bennett, Geoffrey Berry, Anneke Blackburn, Meagan Brennan, Melissa Brown, Michael Buckley, J. Burke, Phyllis Butow, Keith Byron, David Callen, Ian Campbell, G. Chenevix-Trench, Christine Clarke, Alison Colley, Dick Cotton, Jisheng Cui, Bronwyn Culling, Margaret Cummings, Sarah-Jane Dawson, Joanne Dixon, Alexander Dobrovic, Tracy Dudding, Ted Edkins, M. Eisenbruch, G. Farshid, Susan Fawcett, Michael Field, Frank Firgaira, Jean Fleming, John Forbes, Michael Friedlander, Clara Gaff, Mac Gardner, M. Gattas, Peter George, G. Giles, G. Gill, Jack Goldblatt, Sian Greening, S. Grist, Eric Haan, Marion Harris, Stewart Hart, N. Hayward, J. Hopper, Evelyn Humphrey, Mark Jenkins, Alison Jones, R. Kefford, Judy Kirk, James Kollias, Sergey Kovalenko, Sunil Lakhani, Jennifer Leary, Jacqueline Lim, Geoff Lindeman, Lara Lipton, Lizz Lobb, Mariette Maclurcan, Graham Mann, Deb Marsh, M. Mccredie, Michael McKay, Sue-Anne McLachlan, Bettina Meiser, R. Milne, Gillian Mitchell, Beth Newman, Imelda O’Loughlin, Lester Peters, K. Phillips, Melanie Price, Jeanne Reeve, Tony Reeve, Gina Rinehart, Bridget Robinson, Elizabeth Salisbury, J. Sambrook, Christobel Saunders, C. Scott, Elizabeth Scott, Rodney Scott, Andrew Shelling, M. Southey, A. Spurdle, Graeme Suthers, Donna Taylor, Christopher Tennant, Heather Thorne, S. Townshend, Kathy Tucker, Janet Tyler, Deon Venter, J. Visvader, Ian Walpole, Robin Ward, Paul Waring, Bev Warner, Graham Warren, Elizabeth Watson, Rachael Williams, Judy Wilson, Ingrid Winship, Adele Green, Dorota Gertig, Penny Webb (2007)
Genome-wide association study identifies novel breast cancer susceptibility lociNature, 447
-
D. Mauri, N. Pavlidis, N. Polyzos, J. Ioannidis (2006)
Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis.Journal of the National Cancer Institute, 98 18
-
Xiaoxian Li, M. Lewis, Jian Huang, C. Gutierrez, C. Osborne, Meng-Fen Wu, S. Hilsenbeck, A. Pavlick, Xiaomei Zhang, G. Chamness, H. Wong, J. Rosen, Jenny Chang (2008)
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.Journal of the National Cancer Institute, 100 9
-
P. Wülfing, J. Borchard, H. Buerger, S. Heidl, K. Zänker, L. Kiesel, B. Brandt (2006)
HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer PatientsClinical Cancer Research, 12
-
N. Shafee, Christopher Smith, Shuanzeng Wei, Y. Kim, G. Mills, G. Hortobagyi, E. Stanbridge, E. Lee (2008)
Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors.Cancer research, 68 9
-
M. Pegram, G. Konecny, D. Slamon (2000)
The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.Cancer treatment and research, 103
-
W. Park, M. Kim, D. Shin, Jung Lee, K. Choi, J. Kim, D. Park, C. Lee, M. Sol (2012)
Ciliated adenocarcinomas of the lung: a tumor of non-terminal respiratory unit originModern Pathology, 25
-
M. Press, D. Slamon, K. Flom, Jinha Park, Jian‐Yuan Zhou, L. Bernstein (2002)
Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 20 14
-
J. Cortes, M. O'Dwyer (2004)
Clonal evolution in chronic myelogenous leukemia.Hematology/oncology clinics of North America, 18 3
-
Suling Liu, Shawn Clouthier, M. Wicha (2012)
Role of microRNAs in the Regulation of Breast Cancer Stem CellsJournal of Mammary Gland Biology and Neoplasia, 17
-
A. Lipton, W. Köstler, K. Leitzel, Suhail Ali, J. Sperinde, J. Weidler, A. Paquet, T. Sherwood, Weidong Huang, M. Bates (2010)
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization‐positive patients with metastatic breast cancer treated with trastuzumabCancer, 116
-
Lauren Campbell, K. Polyak (2007)
Breast Tumor Heterogeneity: Cancer Stem Cells or Clonal Evolution?Cell Cycle, 6
-
Jeffrey Magee, E. Piskounova, S. Morrison (2012)
Cancer stem cells: impact, heterogeneity, and uncertainty.Cancer cell, 21 3
-
J. Long, Q. Cai, H. Sung, Jiajun Shi, Ben Zhang, Ji-Yeob Choi, W. Wen, Ryan Delahanty, W. Lu, Yu-Tang Gao, Hongbing Shen, Sue-Kyung Park, Kexin Chen, Chen-Yang Shen, Z. Ren, C. Haiman, K. Matsuo, M. Kim, U. Khoo, M. Iwasaki, Ying Zheng, Y. Xiang, K. Gu, N. Rothman, Wenjing Wang, Zhibin Hu, Yao Liu, K. Yoo, D. Noh, B. Han, M. Lee, Hong Zheng, Lina Zhang, Pei‐Ei Wu, Y. Shieh, S. Chan, Shenming Wang, Xiaoming Xie, Sung-Won Kim, B. Henderson, L. Marchand, Hidemi Ito, Y. Kasuga, S. Ahn, H. Kang, K. Chan, H. Iwata, S. Tsugane, Chun Li, X. Shu, D. Kang, W. Zheng (2012)
Genome-Wide Association Study in East Asians Identifies Novel Susceptibility Loci for Breast CancerPLoS Genetics, 8
-
C. Cobaleda, J. Cruz, R. González-Sarmiento, I. Sánchez-García, J. Pérez-Losada (2008)
The Emerging Picture of Human Breast Cancer as a Stem Cell-based DiseaseStem Cell Reviews, 4
-
D. Dingli, J. Pacheco (2011)
Stochastic dynamics and the evolution of mutations in stem cellsBMC Biology, 9
-
H. Korkaya, M. Wicha (2009)
HER-2, Notch, and Breast Cancer Stem Cells: Targeting an Axis of EvilClinical Cancer Research, 15
-
R. Tuma (2007)
Inconsistency of HER2 test raises questions.Journal of the National Cancer Institute, 99 14
-
Jessica Kao, K. Salari, Melanie Bocanegra, Yoon-La Choi, L. Girard, Jeet Gandhi, Kevin Kwei, T. Hernandez-Boussard, Pei Wang, A. Gazdar, J. Minna, J. Pollack (2009)
Molecular Profiling of Breast Cancer Cell Lines Defines Relevant Tumor Models and Provides a Resource for Cancer Gene DiscoveryPLoS ONE, 4
- Publisher
- Springer Journals
- Copyright
- Copyright © 2012 by Springer Science+Business Media, LLC
- Subject
- Medicine & Public Health; Internal Medicine; Oncology; Surgical Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-012-0093-5
- Publisher site
- See Article on Publisher Site
Abstract
Although the heterogeneity of breast cancer has long been recognized, the hierarchical organization and existence of tumor initiating subpopulation within breast tumors was not known until the last decade. These tumor initiating cells called cancer stem cells (CSCs) display features of stem cells such as unlimited ability to self-renew and lineage differentiation. Accumulating evidence now suggests that by virtue of their relative resistance to both radiation and chemotherapy, these cells contribute to resistance and relapse following therapy. Utilizing cell cultures and mouse xenograft models, we and others demonstrated that breast CSCs have far greater invasive and metastatic potential than differentiated tumor cells which comprise the tumor bulk. Altogether, these studies suggest that targeting and elimination of breast CSCs may be required to improve patient outcome. In this review, we will discuss recent developments in breast CSC research and advances in CSC specific targeted therapies that are in preclinical and clinical trials.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Oct 12, 2012